Documents
Cat#: VRS-0124-YT5194
Lenti-SARS-CoV-2 S Pseudovirus [β-Galactosidase, MLV Packaging System]
Lenti-SARS-CoV-2 S Pseudovirus is produced by cotransfecting the cell line TELCeB6 expressing β-Galactosidase and the plasmids encoding the S-protein. Pseudovirus-containing supernatant was harvested 48 h following transfection. The supernatant was cleared of cell debris by centrifugation and filtered through a 0.45-μm-pore-size filter. The produced pseudoviruses carry SARS-CoV-2 S proteins, which is a powerful tool for SARS-CoV-2 vaccine and entry inhibitor research.
Made to Order Requirements
Your choose infomation:
CLEAR(Note: Please select the requirements to fit you project. If you have any other requirements, please specify. If no specific requirements, you don't need to select any button.)
- Product Summary
- Packaging, Storage & Formulations
- Target Details
Product Summary
| Type : | Pseudovirus |
| Virus Name : | Severe Acute Respiratory Syndrome Coronavirus 2 |
| Virus Packaging Protein : | S |
| Packaging System : | MLV Packaging System |
| Packaging Cell : | TELCeB6 |
| Reporter Gene : | β-Galactosidase |
| Titer : | >1^10 virus copies/mL |
| Application Notes : | The pseudovirus can be usd for the following applications: 1. Antibody neutralization assay, Serum neutralization assay. 2. As virus standard alternative in diagnostic assay or others. 3. Drug screening including vaccine development, viral entry inhibitor development. 4. As a safe virology tool to discover the virus entry mechanisms. |
Packaging, Storage & Formulations
| Form : | Liquid |
| Storage : | Store at -80°C and stable for 1 year from the date of shipment, avoiding freeze/thaw cycles. |
| Shipping : | Dry ice |
| Note : | The pseudovirus can be used under BSL-2 conditions. Please reach out to our scientists for detailed instructions or guidelines of the pseudovirus. |
Target Details
| Introduction : | An outbreak of a novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was reported since last December, 2019. Now COVID-19 is an emerging, rapidly evolving situation, and has become a pandemic.SARS-CoV-2 consists of four structural proteins, including S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. As an important envelope protein, S protein is identified as the protein responsible for virus entry into human cells, and S protein is the major target for anti-SARS-CoV-2 therapeutics discovery. |
| Alternative Names : | SARS-CoV-2, 2019nCoV, COVID-19, S, Spike, Pseudovirus, Spike Pseudovirus, S Pseudovirus, SARS-CoV-2 Spike Pseudovirus, SARS-CoV-2 S Pseudovirus, COVID-19 Spike Pseudovirus, COVID-19 S Pseudovirus |
| Gene ID : | 43740568 |
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
pepFastX™ Platform
If no antibody is available for your research, we recommend our novel pepFastX™ antibody discovery platform. The mAb products can be delivered within 2-3 months.
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support